Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Psychopharmacology (Berl) ; 239(2): 339-350, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-34783884

RESUMO

RATIONALE: The use of intravenous valproate is not approved for clinical practice in psychiatry. Literature data pointed out for a potential usefulness of this route of administration for valproate, but there is no actual consensus. OBJECTIVES: The aim of the present systematic review is to assess the effectiveness of intravenous valproate in agitation as well as general safety. METHODS: A systematic review of studies evaluating the use of intravenous valproate in agitation was conducted. Additionally, safety was evaluated in all randomized trials involving the use of intravenous valproate in all medical conditions (epilepsy, migraine and psychiatric conditions). RESULTS: For the systematic review on effectiveness in agitation, the search yielded 965 articles overall. After removing duplicates, 9411 articles were screened by title and abstract, and 39 of these were evaluated at a full-text level. Six studies were considered eligible for qualitative synthesis: one RCT and case report (n = 3), followed by cohort studies (n = 2). For the systematic review on safety, twenty-two RCTs were considered eligible for quantitative synthesis. CONCLUSION: Intravenous valproate seems efficacious in reducing agitation in psychiatric patients; it generally appears safe compared to other neuroleptics or antiepileptics. However, the evidence is still not strong as it  relies mainly on open-label studies or case series.


Assuntos
Antipsicóticos , Ácido Valproico , Anticonvulsivantes , Humanos , Ácido Valproico/efeitos adversos
2.
Psychiatr Serv ; 71(3): 284-288, 2020 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-31640524

RESUMO

OBJECTIVE: The authors conducted a cross-sectional survey to investigate the association between episodes of patient aggression and burnout among mental health professionals. METHODS: Scores of the Maslach Burnout Inventory (MBI) among 183 participants who completed a questionnaire on violence exposure were used as the outcome. Demographic and work-related variables were examined as potential moderators of the association between aggression and burnout. RESULTS: Lifetime exposure to verbal or object aggression was associated with higher MBI scores. In stepwise regression, MBI score was positively associated with having experienced recent verbal aggression and with the number of symptoms experienced immediately after the worst event. MBI score was negatively associated with working in a university psychiatric inpatient unit. The association between verbal aggression and burnout was significant only among women. CONCLUSIONS: Workplace violence may have a significant negative impact on subjective well-being and patient care and may contribute to burnout among mental health professionals.


Assuntos
Esgotamento Profissional/psicologia , Pessoal de Saúde/psicologia , Unidade Hospitalar de Psiquiatria , Violência no Trabalho/psicologia , Adulto , Idoso , Agressão/psicologia , Estudos Transversais , Feminino , Pessoal de Saúde/estatística & dados numéricos , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários
3.
Psychiatry Res ; 262: 469-476, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-28988102

RESUMO

Notwithstanding major depressive disorder (MDD) is a recurring and chronic condition, relatively few variables have consistently been shown to predict its course. Residual depressive symptoms may be associated with disability and functional impairment but few studies evaluated clinical correlates associated with these symptoms and their impact on functioning after adjustment for potential confounders. Therefore, our study aimed to investigate factors associated with residual depressive symptoms and their impact on the course of MDD. The sample consisted of 210 consecutive MDD euthymic outpatients (67.6% females; mean age = 52.1 ± 15.5), admitted to the Section of Psychiatry, University of Genoa (Italy). Residuals depressive symptoms were significantly associated with female gender; use of short half-life benzodiazepines; longer duration of the current depressive episode; higher number of illness episodes; and higher duration of illness. Conversely, prior treatment with first-generation antipsychotics, later age of illness onset and first hospitalization were less frequently observed among patients with residual symptoms. After multivariate analyses, only duration of current illness episodes (ß = 0.003; p = <0.005) and substance abuse (ß = 0.042; p = <0.05) remained significantly associated with residual symptoms. Our findings indicate that residual depressive symptoms conferred a pernicious illness course in this specific cohort of MDD patients. Future trials mainly targeting these burdensome symptoms are warranted.


Assuntos
Transtorno Depressivo Maior/tratamento farmacológico , Transtorno Depressivo Maior/fisiopatologia , Avaliação de Resultados em Cuidados de Saúde , Fatores de Tempo , Adulto , Idoso , Estudos de Coortes , Transtorno Depressivo Maior/epidemiologia , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA